Viridian Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.32 |
0.20 |
45.89 |
242.43 |
650.96 |
992.60 |
| Przychód Δ r/r |
0.00% |
-38.07% |
23256.04% |
428.24% |
168.51% |
52.48% |
| Przychód (min) |
0.24 |
0.11 |
44.25 |
242.43 |
355.07 |
541.42 |
| Przychód (max) |
0.41 |
0.36 |
47.54 |
242.43 |
1,183.56 |
1,804.74 |
| EBITDA (średnia) |
-0.32 |
-0.20 |
-45.89 |
-242.43 |
-650.96 |
-992.60 |
| EBIT (średnia) |
-0.32 |
-0.20 |
-45.89 |
-242.43 |
-650.96 |
-992.60 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-270.28 |
-274.68 |
-260.33 |
-142.21 |
76.94 |
252.56 |
| Zysk netto % |
-85185.82% |
-139785.74% |
-567.24% |
-58.66% |
11.82% |
25.44% |
| EPS (średnia) |
-4.00 |
-4.05 |
-3.80 |
-2.05 |
1.13 |
3.72 |
| Liczba analityków (Przychody) |
11 |
8 |
14 |
10 |
4 |
5 |
| Liczba analityków (EPS) |
12 |
10 |
13 |
9 |
4 |
3 |
| symbol |
VRDN |
VRDN |
VRDN |
VRDN |
VRDN |
VRDN |